Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

What happened

Innate Pharma said AstraZeneca moved the expected high-level data readout for the PACIFIC-9 Phase 3 trial to the first half of 2027, from the second half of 2026 previously. The company said the change reflects the event-driven nature of the study, and enrollment is complete.

Confirmed

Global impact / market context

Innate Pharma earns milestone and royalty payments from monalizumab, which AstraZeneca licensed in full in 2018. A later readout delays any possible payout and keeps investors waiting longer for proof the drug works, which can weigh on the shares and on the company's ability to raise new money.

Analyst inference

Trial readouts in this study depend on how many patients reach a measured outcome, not a fixed calendar date, so timelines can slip without any safety or efficacy problem. Investors must now treat 2027, not 2026, as the catalyst date when judging Innate Pharma's news flow and cash runway.

Analyst inference

What to watch

1. Innate Pharma said the PACIFIC-9 readout is now expected in the first half of 2027, and that enrollment in the AstraZeneca-led trial is complete. Confirmed
2. Watch whether Innate Pharma updates its cash runway guidance, because a later milestone payment could push the company to raise money sooner or cut spending. Analyst inference
3. Watch AstraZeneca's quarterly results and conference calls for any comment on the PACIFIC-9 timeline, which would confirm whether the first-half 2027 date still holds. Analyst inference

Evidence

• Original source link unavailable